SIFASI 2000IU

Distributor inventory | Vial

Treatment of female infertility due to anovulation (ovulation trigger in assisted reproduction), luteal phase support as prescribed; treatment of male hypogonadotropic hypogonadism and infertility (to stimulate testosterone/spermatogenesis); induction of puberty in selected boys with hypogonadotropic hypogonadism; cryptorchidism not due to anatomical obstruction (selected cases).

hCG acts like luteinizing hormone (LH). In women it triggers final maturation and release of the egg (ovulation) and supports corpus luteum progesterone production. In men it stimulates Leydig cells in the testes to produce testosterone, supporting sperm production.

Injection to be given only under medical supervision. Reconstitute the vial with the provided sterile diluent (if supplied) and use immediately after mixing; administer as directed (IM or SC depending on protocol). Dose and timing depend on indication (e.g., ovulation trigger in ART) and must follow the fertility specialist’s plan.

Injection site pain/redness, headache, fatigue, irritability, abdominal pain/bloating, nausea/vomiting, breast tenderness, edema, mood changes

Prescription-only fertility hormone. In women, risk of ovarian hyperstimulation syndrome (OHSS), ovarian enlargement/cysts and thromboembolism—seek urgent care for severe abdominal pain, rapid weight gain, breathing difficulty or reduced urination. Increased risk of multiple pregnancy with fertility treatment. Contraindicated in hormone-dependent tumors (e.g., ovarian/breast/prostate), primary ovarian failure, uncontrolled thyroid/adrenal disorders, pituitary tumor, unexplained vaginal bleeding, or known hypersensitivity. Use caution in patients with thrombotic risk, epilepsy, migraine, asthma, cardiac/renal disease. In males, may cause gynecomastia, fluid retention and worsen conditions sensitive to androgens.